Clinical trials: Relapsed/ Refractory Multiple Myeloma
Graft Versus Host Disease, Leukemia
Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
RATIONALE: Giving chemotherapy and total-body irradiation before a donor bone marrow transplant or peripheral blood stem cell transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune…
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00265837
- Testing
- graft versus host disease prophylaxis/therapy, allogeneic bone marrow transplantation, in vitro-treated bone marrow transplantation
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Multiple Myeloma
Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma
This pilot phase II trial studies how well giving bortezomib and cyclophosphamide together with chloroquine works in treating patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT01438177
- Testing
- Velcade, Cyclophosphamide, Chloroquine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- NYU Langone Health
Refractory Multiple Myeloma, Relapse Multiple Myeloma
Elranatamab in R/R Multiple Myeloma
This research is being done to see if the study drug, elranatamab, reduces the risk of disease progression (worsening disease) after idecabtagene vicleucel in relapsed refractory multiple myeloma.
- Conditions
- Refractory Multiple Myeloma, Relapse Multiple Myeloma, Multiple Myeloma
- Trial name
- NCT06138275
- Testing
- Elranatamab
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Massachusetts General Hospital
Multiple Myeloma, Plasma Cell Leukemia
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
This is a Phase 1 study during which patients with relapsed or refractory multiple myeloma (MM) or plasma cell leukemia (PCL) will receive investigational study drug ARRY-520 and bortezomib, with or without dexamethasone, with…
- Trial name
- NCT01248923
- Testing
- ARRY-520, KSP(Eg5) inhibitor; intravenous, Bortezomib, proteasome inhibitor; intravenous or subcutaneous, Dexamethasone, steroid; oral
- Where
- 13 sites in United States
- Volunteers
- 55 people
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
Multiple Myeloma
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
The purpose of the study is to compare the progression-free survival (PFS) of once-weekly carfilzomib dosing in combination with dexamethasone to twice-weekly carfilzomib dosing in combination with dexamethasone in adults with…
- Trial name
- ARROW (NCT02412878)
- Testing
- Carfilzomib, Dexamethasone
- Where
- 140 sites in United States, Australia and 18 more
- Volunteers
- 478 people
- Sponsor
- Amgen
Relapsed or Refractory Multiple Myeloma
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.
- Trial name
- SUCCESSOR-2 (NCT05552976)
- Testing
- Mezigdomide, Carfilzomib, Dexamethasone
- Where
- 204 sites in United States, Argentina and 25 more
- Volunteers
- 606 people
- Sponsor
- Bristol-Myers Squibb
Relapsed/Refractory Multiple Myeloma
A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
This was a Phase 3, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of venetoclax plus bortezomib and dexamethasone in participants with relapsed or refractory multiple myeloma…
- Trial name
- Bellini (NCT02755597)
- Testing
- Venetoclax, Bortezomib, Dexamethasone
- Where
- 97 sites in United States, Australia and 14 more
- Volunteers
- 291 people
- Sponsor
- AbbVie
Multiple Myeloma
Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma
This research study is studying a combination of drugs as a possible treatment for multiple myeloma. The drugs that will be administered are: ABI-009 (nab-rapamycin) Pomalidomide Dexamethasone
- Trial name
- NCT03657420
- Testing
- ABI-009, Pomalidomide, Dexamethasone
- Where
- United States
- Sponsor
- Massachusetts General Hospital
Multiple Myeloma
A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma
This is a single-arm, open-label, dose-escalation study to evaluate the safety, tolerability, cellular kinetics and initial efficacy of CAR-T cell therapy targeting GPRC5D in multiple myeloma subjects who have failed the standard…
- Trial name
- NCT05016778
- Testing
- GPRC5D-CAR-T
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Zhejiang University
Chronic Myeloproliferative Disorders, Leukemia
T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
RATIONALE: Donor peripheral stem cell transplantation may be able to replace bone marrow and immune cells that were destroyed by chemotherapy. Sometimes the transplanted cells from a donor are rejected by the body's normal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00080925
- Testing
- filgrastim, graft-versus-tumor induction therapy, rituximab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Multiple Myeloma
A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
This is a multicenter, open-label, Phase 1b study to determine the recommended dose and regimen of durvalumab either as monotherapy or in combination with POM with or without low dose dex in subjects with RRMM.
- Trial name
- NCT02616640
- Testing
- Durvalumab, Pomalidomide, Dexamethasone
- Where
- 22 sites in United States, Canada and 5 more
- Volunteers
- 114 people
- Sponsor
- Celgene
Multiple Myeloma
Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma
To determine the maximum tolerated dose of, and response to, PRLX 93936 as treatment for patients with relapsed or relapsed/refractory multiple myeloma.
- Trial name
- NCT01695590
- Testing
- PRLX 93936
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Prolexys Pharmaceuticals
Multiple Myeloma
CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma
The purpose of the study is to select the dose regimen of CDC-501 that provides the most promising evidence of efficacy.
- Trial name
- NCT00044018
- Testing
- CDC-501
- Where
- 4 sites in United States
- Volunteers
- 102 people
- Sponsor
- Celgene
Cancer Survivor, Chronic Myeloproliferative Disorders
Presence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor Stem Cell Transplant
RATIONALE: Studying samples of semen from cancer survivors in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Conditions
- Cancer Survivor, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT01077440
- Testing
- DNA analysis, polymerase chain reaction, flow cytometry
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Vanderbilt University
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
A Study of CD19/BCMA-targeted CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia, B-cell Non-Hodgkin's Lymphoma and Multiple Myeloma.
- Conditions
- Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphocytic Leukaemia Refractory
- Trial name
- NCT04603872
- Testing
- CD19/BCMA Targeted CAR T-cells and dasatinib, CD19/BCMA Targeted CAR T-cells
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Zhejiang University
Multiple Myeloma
Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)
Study Phase: phase 1 and phase 2 Objective: Evaluation of the effect of lenalidomide, cyclophophamide and prednisone (REP) in patients with relapsed multiple myeloma previously treated with lenalidomide Study design: prospective…
- Trial name
- REPEAT (NCT01352338)
- Testing
- Lenalidomide, endoxan, prednisone
- Where
- 3 sites in Netherlands
- Volunteers
- 82 people
- Sponsor
- UMC Utrecht
Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM)
18F-Fluciclovine PET/CT in Multiple Myeloma
Background: Multiple myeloma (MM) is an incurable cancer of certain blood cells. MM often returns after treatment, and most people survive only 5 to 8 years after diagnosis.
- Conditions
- Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Relapsed and/or Refractory Multiple Myeloma (RRMM)
- Trial name
- NCT06103838
- Testing
- 18F-fluciclovine injection, 18F-FDG PET/CT
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed or Refractory Multiple Myeloma
Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095)
The purpose of this study is to evaluate the clinical activity of vorinostat in combination with bortezomib in participants with relapsed or refractory multiple myeloma after at least 2 prior treatment regimens.
- Trial name
- NCT00773838
- Testing
- Vorinostat, Bortezomib, Dexamethasone
- Volunteers
- 143 people
- Sponsor
- Merck Sharp & Dohme LLC
Relapsed/Refractory Multiple Myeloma
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of ABBV-453 in adult participants with…
- Trial name
- NCT05308654
- Testing
- ABBV-453, Dexamethasone, Daratumumab
- Where
- 21 sites in United States, Australia and 2 more
- Volunteers
- 34 people
- Sponsor
- AbbVie
Relapsed or Refractory Multiple Myeloma
A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers
The primary objective was to describe the safety profile of carfilzomib plus dexamethasone regimen in adults with relapsed or refractory multiple myeloma (RRMM) with 1 to 3 prior lines of therapy at study entry.
- Trial name
- NCT03512353
- Testing
- Dexamethasone, Carfilzomib
- Where
- 31 sites in United States
- Volunteers
- 7 people
- Sponsor
- Amgen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.